Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4661444 | 0.78 | LMNA (0.61) | LMNASMN1; SMN2NFKB1MAOBKDM4E | |
| SCHEMBL4661446 | 0.78 | LMNA (0.61) | LMNASMN1; SMN2NFKB1MAOBKDM4E | |
| SCHEMBL3369122 | 0.77 | CES2 (0.42) | TRPA1LMNASMN1; SMN2NFKB1KDM4E | |
| SCHEMBL9233997 | 0.77 | LMNA (0.53) | LMNASMN1; SMN2NFKB1GRIN2DGRIN3B | |
| SCHEMBL28450866 | 0.77 | LMNA (0.60) | LMNASMN1; SMN2NFKB1GRIN2DGRIN3B | |
| SCHEMBL10174974 | 0.77 | TAS2R14 (0.52) | TRPA1LMNASMN1; SMN2MAOBKDM4E | |
| SCHEMBL11557463 | 0.76 | LMNA (0.52) | LMNASMN1; SMN2NFKB1MAOBKDM4E | |
| SCHEMBL3369090 | 0.75 | TRPA1 (0.60) | TRPA1LMNASMN1; SMN2APPKDM4E | |
| SCHEMBL14198042 | 0.75 | NFKB1 (0.52) | LMNASMN1; SMN2NFKB1GRIN2DGRIN3B | |
| SCHEMBL31147155 | 0.75 | NFKB1 (0.52) | LMNASMN1; SMN2NFKB1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476435-B1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-7022718-B2 | Pyridine and pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | BOEHRINGER MARKUS (CH) | 2005-06-30 | — | — | US | disclosed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
| EP-0537949-B1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY CO ELI (GB) | 1998-07-01 | — | — | EP | disclosed |
| US-5284868-A | Naphthopyran derivatives; for autoimmune diseases, cancer | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| US-5281619-A | Administering naphtho(1,2-B)pyran derivatives | ELI LILLY AND COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0537949-A1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY INDUSTRIES LIMITED (GB) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, G6PC1 | TRPA1 3965/4885LMNA 4849/4885SMN1; SMN2 2696/4885 |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, PDXK | TRPA1 3259/4885LMNA 4794/4885SMN1; SMN2 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.